Last reviewed · How we verify
ZN-c5
At a glance
| Generic name | ZN-c5 |
|---|---|
| Sponsor | Zeno Alpha Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ZN-c5 in Subjects With Breast Cancer (PHASE1, PHASE2)
- A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer (PHASE1)
- A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS (PHASE1)
- A Study of ZN-c5 in Participants With Breast Cancer (PHASE1)
- A Food Effect Study With ZN-c5 in Healthy Post-Menopausal Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZN-c5 CI brief — competitive landscape report
- ZN-c5 updates RSS · CI watch RSS
- Zeno Alpha Inc. portfolio CI